Medical and Clinical Disclaimer

Last Updated: August 2026

EMERGENCY NOTICE (Spinal Cord Compression & ICANS): If you or a loved one are experiencing acute or rapidly progressive lower extremity weakness, stumbling, numbness spreading up the torso, loss of bowel/bladder control, or severe confusion following CAR-T therapy, please call your local emergency services (911 in the US/Canada, 999 in the UK, 112 in the EU) or proceed immediately to the nearest Emergency Room.

1. Informational & Supportive Purpose Only

The content provided on NeuroOncoGuides (accessible at neuro.oncoguides.org and across the OncoGuides Network) is published solely for educational, supportive, and informational purposes. The information, interactive NCI-CTCAE severity calculators, cryotherapy infusion protocols, neuropathic medication profiles, and non-profit mobility grant directories are designed to support, not replace, the clinical judgment of an oncologist, neurologist, or healthcare team.

2. No Doctor-Patient Relationship

Use of this website, including calculation of CTCAE neuropathy scores or logging of numbness progression in the private sensory vault, does not establish a doctor-patient relationship, clinical consultation, or medical prescription. You should never delay seeking medical advice, disregard professional medical counsel, or modify chemotherapy dosages without explicit instructions from your oncologist.

3. Chemotherapy Neuropathy Variability

Susceptibility to neurotoxic chemotherapy (e.g., Paclitaxel, Docetaxel, Oxaliplatin, Cisplatin, Bortezomib) varies widely based on cumulative dosages, schedule, diabetes status, and individual pharmacogenomics. Chemotherapy dose reductions must always be managed by your treating oncologist.

4. Financial Aid & Assistive Grants Directory

While NeuroOncoGuides continuously audits and verifies the non-profit charities and patient assistance funds listed in our directory, fund availability, income eligibility criteria, and maximum grant caps change frequently based on annual foundation funding cycles.